Q-omics provides the consensus-scored PRR23A profile across patient tissues and cancer cell-line models. PRR23A expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRR23A is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, PRR23A RNA expression shows 8,376 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where PRR23A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR23A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR23A survival associations across molecular data types. PRR23A RNA expression shows survival associations in the most cancer types (13), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR23A RNA expression–survival associations across cancer types. High PRR23A expression shows unfavorable associations in ACC, KICH, LIHC and THCA, but favorable associations in HNSC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRR23A RNA expression.
This table summarizes PRR23A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRR23A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR23A shows higher tumor expression in HNSC and THCA. The HNSC box plot shows higher PRR23A RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .029).
This table shows molecular features associated with PRR23A in patient tissues and cancer cell lines. In patient samples, PRR23A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR23A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
